Achmea Investment Management B.V. Sells 6,156 Shares of AbbVie Inc (ABBV)
Achmea Investment Management B.V. trimmed its stake in AbbVie Inc (NYSE:ABBV) by 5.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,553 shares of the company’s stock after selling 6,156 shares during the period. Achmea Investment Management B.V.’s holdings in AbbVie were worth $8,304,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ABBV. MCF Advisors LLC grew its holdings in AbbVie by 15.3% during the 1st quarter. MCF Advisors LLC now owns 4,556 shares of the company’s stock worth $297,000 after acquiring an additional 606 shares during the period. Greatmark Investment Partners Inc. grew its holdings in AbbVie by 1.7% during the 1st quarter. Greatmark Investment Partners Inc. now owns 33,936 shares of the company’s stock worth $2,211,000 after acquiring an additional 560 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in AbbVie by 33.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 461,768 shares of the company’s stock worth $30,441,000 after acquiring an additional 115,550 shares during the period. Community Bank N.A. grew its holdings in AbbVie by 1.6% during the 1st quarter. Community Bank N.A. now owns 66,262 shares of the company’s stock worth $4,317,000 after acquiring an additional 1,015 shares during the period. Finally, Massmutual Trust Co. FSB ADV grew its holdings in AbbVie by 16.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 98,704 shares of the company’s stock worth $6,432,000 after acquiring an additional 14,194 shares during the period. Institutional investors and hedge funds own 69.32% of the company’s stock.
In related news, VP Robert A. Michael sold 6,699 shares of the firm’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the transaction, the vice president now owns 10,007 shares of the company’s stock, valued at approximately $880,616. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the completion of the transaction, the chairman now directly owns 492,030 shares in the company, valued at approximately $46,255,740.30. The disclosure for this sale can be found here. Insiders have sold a total of 414,335 shares of company stock worth $39,258,362 in the last three months. Insiders own 0.23% of the company’s stock.
AbbVie Inc (ABBV) opened at $97.45 on Friday. The stock has a market cap of $153,736.20, a PE ratio of 18.14, a PEG ratio of 1.34 and a beta of 1.52. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 1 year low of $59.27 and a 1 year high of $98.87.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.21 EPS. research analysts forecast that AbbVie Inc will post 5.55 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is 62.29%.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.